{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:02:12Z","timestamp":1785261732553,"version":"3.55.0"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["252102310490"],"award-info":[{"award-number":["252102310490"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myasthenia gravis (MG) is a B-cell-mediated autoimmune disease characterized by impaired neuromuscular transmission. Although genetic predisposition and thymic abnormalities are well recognized, they cannot fully explain the increasing incidence and regional heterogeneity of MG, highlighting the potential contribution of environmental factors. Bisphenol A (BPA), a ubiquitous endocrine-disrupting chemical, exhibits estrogenic activity, immunomodulatory effects, and mitochondrial toxicity, and has been implicated in multiple autoimmune disorders. However, the potential role of BPA in MG pathogenesis remains largely unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>BPA-related targets and MG-associated genes were collected from public databases, and overlapping targets were identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to explore the biological functions and pathways of the overlapping targets. Candidate targets were screened using four machine-learning algorithms, including least absolute shrinkage and selection operator (LASSO) regression, support vector machine-recursive feature elimination (SVM-RFE), random forest (RF), and extreme gradient boosting (XGBoost). Differential expression and diagnostic performance were validated using the Gene Expression Omnibus (GEO) dataset GSE85452. Immune infiltration was assessed using CIBERSORT. Molecular docking and molecular dynamics (MD) simulations were conducted to evaluate the potential binding stability and interaction modes between BPA and key target proteins. In addition, C2C12 myoblasts were treated with different concentrations of BPA for 24 h, and cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay. Based on the cell viability results, 50 \u03bcM BPA was selected for quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analyses of key genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 225 overlapping targets were identified between BPA exposure-related targets and MG-associated genes. Enrichment analyses showed that these targets were mainly associated with ion transport, membrane potential regulation, muscle system processes, immune signaling, apoptosis, endocrine resistance, and AGE\u2013RAGE signaling pathways.Four machine-learning algorithms identified cholinergic receptor nicotinic beta 1 subunit (CHRNB1), KRAS proto-oncogene, GTPase (KRAS), phosphomannomutase 2 (PMM2), and toll-like receptor 4 (TLR4) as candidate targets. Validation in the GSE85452 dataset showed that CHRNB1, PMM2, and TLR4 were significantly upregulated in MG samples compared with control samples, whereas KRAS showed no significant difference. receiver operating characteristic (ROC) analysis further demonstrated that CHRNB1, PMM2, and TLR4 had good diagnostic performance, with area under the ROC curve (AUC) values of 0.827, 0.856, and 0.821,respectively. Immune infiltration analysis revealed altered immune cell infiltration patterns and associations between key targets and specific immune cell subsets. Molecular docking predicted favorable binding of BPA to CHRNB1, PMM2, and TLR4, with binding energies of \u22127.4, \u22125.7, and \u22125.8 kcal\/mol, respectively. MD simulations further supported the potential stability of these BPA-target complexes. In vitro experiments showed that BPA reduced C2C12 cell viability in a concentration-dependent manner. qRT-PCR validation showed that treatment with 50 \u03bcM BPA significantly upregulated Chrnb1 expression, while downregulating Pmm2 and Tlr4 expression.Western blot analysis further confirmed that BPA exposure significantly decreased the protein expression of TLR4 and PMM2, while increasing that of CHRNB1 in C2C12 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides integrated computational and experimental evidence that BPA exposure may be associated with MG-related molecular alterations. BPA may affect MG-related biological processes through the regulation of ion transport, neuromuscular signaling, immune activation, and glycosylation-related metabolism. CHRNB1, PMM2, and TLR4 may serve as potential molecular links between BPA exposure and MG-related pathological processes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0354138","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:42:45Z","timestamp":1785260565000},"page":"e0354138","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bisphenol A exposure in myasthenia gravis: Potential targets and mechanisms revealed by network toxicology and molecular dynamics"],"prefix":"10.1371","volume":"21","author":[{"given":"Shupeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8735-0235","authenticated-orcid":true,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"3","key":"pone.0354138.ref001","first-page":"119","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"DA Garc\u00eda Est\u00e9vez","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"pone.0354138.ref002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"AS Carr","year":"2010","journal-title":"BMC Neurol"},{"issue":"9","key":"pone.0354138.ref003","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neurol.2024.09.006","article-title":"New treatment strategies in Myasthenia gravis","volume":"180","author":"S Attarian","year":"2024","journal-title":"Rev Neurol (Paris)"},{"issue":"3","key":"pone.0354138.ref004","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00415-025-12922-7","article-title":"Myasthenia gravis in 2025: five new things and four hopes for the future","volume":"272","author":"SNM Binks","year":"2025","journal-title":"J Neurol"},{"issue":"7","key":"pone.0354138.ref005","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","article-title":"Heterogeneity in myasthenia gravis: considerations for disease management","volume":"17","author":"A Evoli","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"pone.0354138.ref006","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"NE Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"6","key":"pone.0354138.ref007","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.3390\/ijms24065342","article-title":"Endocrine-Disrupting Chemicals and Disease Endpoints","volume":"24","author":"C Ahn","year":"2023","journal-title":"Int J Mol Sci"},{"key":"pone.0354138.ref008","doi-asserted-by":"crossref","first-page":"119346","DOI":"10.1016\/j.envpol.2022.119346","article-title":"Genotoxic potential of bisphenol A: A review","volume":"306","author":"I \u010eurovcov\u00e1","year":"2022","journal-title":"Environ Pollut"},{"issue":"4","key":"pone.0354138.ref009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10408444.2021.1908224","article-title":"Toxicity of bisphenol analogues on the reproductive, nervous, and immune systems, and their relationships to gut microbiome and metabolism: insights from a multi-species comparison","volume":"51","author":"CM McDonough","year":"2021","journal-title":"Crit Rev Toxicol"},{"issue":"10","key":"pone.0354138.ref010","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1016\/j.fct.2012.07.059","article-title":"A review of dietary and non-dietary exposure to bisphenol-A","volume":"50","author":"T Geens","year":"2012","journal-title":"Food Chem Toxicol"},{"issue":"8","key":"pone.0354138.ref011","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1007\/s00204-024-03793-4","article-title":"Bisphenol A and its analogues: from their occurrence in foodstuffs marketed in Europe to improved monitoring strategies-a review of published literature from 2018 to 2023","volume":"98","author":"I Neri","year":"2024","journal-title":"Arch Toxicol"},{"issue":"1","key":"pone.0354138.ref012","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.taap.2007.12.008","article-title":"Human exposure to bisphenol A by biomonitoring: methods, results and assessment of environmental exposures","volume":"228","author":"W Dekant","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"pone.0354138.ref013","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1289\/ehp.10753","article-title":"Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003\u20132004","volume":"116","author":"AM Calafat","year":"2008","journal-title":"Environ Health Perspect"},{"key":"pone.0354138.ref014","doi-asserted-by":"crossref","first-page":"120341","DOI":"10.1016\/j.envres.2024.120341","article-title":"Temporal and geographic variability of bisphenol levels in humans: A systematic review and meta-analysis of international biomonitoring data","volume":"264","author":"JM Acevedo","year":"2025","journal-title":"Environ Res"},{"issue":"4","key":"pone.0354138.ref015","article-title":"Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs","volume":"21","author":"Materials EFSA Panel on Food Contact","year":"2023","journal-title":"EFSA J"},{"key":"pone.0354138.ref016","doi-asserted-by":"crossref","first-page":"117352","DOI":"10.1016\/j.ecoenv.2024.117352","article-title":"Environmental triggers and future risk of developing autoimmune diseases: Molecular mechanism and network toxicology analysis of bisphenol A","volume":"288","author":"Y Hong","year":"2024","journal-title":"Ecotoxicol Environ Saf"},{"issue":"3","key":"pone.0354138.ref017","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006021","article-title":"Patients with systemic lupus erythematosus (SLE) have an increased bisphenol A methylation score linked to SLE risk genes and selected clinical subphenotypes","volume":"11","author":"H Vestin","year":"2025","journal-title":"RMD Open"},{"key":"pone.0354138.ref018","doi-asserted-by":"crossref","first-page":"153847","DOI":"10.1016\/j.tox.2024.153847","article-title":"Analysis of environmental pollutant Bisphenol F elicited prostate injury targets and underlying mechanisms through network toxicology, molecular docking, and multi-level bioinformatics data integration","volume":"506","author":"S Huang","year":"2024","journal-title":"Toxicology"},{"key":"pone.0354138.ref019","doi-asserted-by":"crossref","first-page":"119480","DOI":"10.1016\/j.jep.2025.119480","article-title":"Application and development trends of network toxicology in the safety assessment of traditional Chinese medicine","volume":"343","author":"X Li","year":"2025","journal-title":"J Ethnopharmacol"},{"issue":"19","key":"pone.0354138.ref020","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.3390\/ijms26199458","article-title":"Utilizing Network Toxicology and Molecular Dynamics Simulations to Efficiently Evaluate the Neurotoxicity and Underlying Mechanisms of the Endocrine-Disrupting Chemical Triclosan","volume":"26","author":"H Wang","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"7","key":"pone.0354138.ref021","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1097\/JS9.0000000000002455","article-title":"Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin B1-induced hepatocellular carcinoma","volume":"111","author":"J Gao","year":"2025","journal-title":"Int J Surg"},{"key":"pone.0354138.ref022","doi-asserted-by":"crossref","first-page":"125708","DOI":"10.1016\/j.jenvman.2025.125708","article-title":"Exploring the toxicological impact of bisphenol a exposure on psoriasis through network toxicology, machine learning, and multi-dimensional bioinformatics analysis","volume":"385","author":"C Feng","year":"2025","journal-title":"J Environ Manage"},{"key":"pone.0354138.ref023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","article-title":"Immunedeconv: An R Package for Unified Access to Computational Methods for Estimating Immune Cell Fractions from Bulk RNA-Sequencing Data","volume":"2120","author":"G Sturm","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"3","key":"pone.0354138.ref024","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","article-title":"User\u2019s guide to correlation coefficients","volume":"18","author":"H Akoglu","year":"2018","journal-title":"Turk J Emerg Med"},{"issue":"12","key":"pone.0354138.ref025","doi-asserted-by":"crossref","first-page":"10370","DOI":"10.3390\/ijms241210370","article-title":"Network Pharmacology, Molecular Docking and Molecular Dynamics to Explore the Potential Immunomodulatory Mechanisms of Deer Antler","volume":"24","author":"L Liu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"pone.0354138.ref026","doi-asserted-by":"crossref","first-page":"1508422","DOI":"10.3389\/fmed.2024.1508422","article-title":"Advances in the genetics of myasthenia gravis: insights from cutting-edge neuroscience research","volume":"11","author":"Z Yixian","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"pone.0354138.ref027","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2174\/1871530321666210210154309","article-title":"The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases","volume":"22","author":"K Sharif","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"9","key":"pone.0354138.ref028","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2174\/1871527313666140806144831","article-title":"Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress","volume":"13","author":"JC T\u00f3bon-Velasco","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"pone.0354138.ref029","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"AR Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"pone.0354138.ref030","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/nu14071414","article-title":"Lipid Metabolism in Inflammation and Immune Function","volume":"14","author":"CJ Andersen","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"pone.0354138.ref031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/biof.1812","article-title":"Myasthenia gravis: The pharmacological basis of traditional Chinese medicine for its clinical application","volume":"48","author":"S Xiaoyue","year":"2022","journal-title":"Biofactors"},{"issue":"7","key":"pone.0354138.ref032","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"AM Schmidt","year":"2001","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0354138.ref033","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.clim.2011.04.013","article-title":"Activation of the receptor for advanced glycation end products (RAGE) exacerbates experimental autoimmune myasthenia gravis symptoms","volume":"141","author":"L Mu","year":"2011","journal-title":"Clin Immunol"},{"issue":"1","key":"pone.0354138.ref034","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbrc.2012.02.121","article-title":"The receptor for advanced glycation endproducts and its ligands in patients with myasthenia gravis","volume":"420","author":"B Moser","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"pone.0354138.ref035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/wjtcm.wjtcm_11_21","article-title":"Network Pharmacology Evaluation Method Guidance - Draft","volume":"7","author":"S Li","year":"2021","journal-title":"World J Tradit Chin Med"},{"issue":"4","key":"pone.0354138.ref036","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/ijms24043730","article-title":"Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review","volume":"24","author":"K Ohno","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"pone.0354138.ref037","doi-asserted-by":"crossref","first-page":"104412","DOI":"10.1016\/j.braindev.2025.104412","article-title":"Clinical and genetic features of congenital myasthenic syndrome due to the muscle acetylcholine receptor genes","volume":"47","author":"J Guan","year":"2025","journal-title":"Brain Dev"},{"issue":"2","key":"pone.0354138.ref038","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/jimd.12461","article-title":"Insight on molecular pathogenesis and pharmacochaperoning potential in phosphomannomutase 2 deficiency, provided by novel human phosphomannomutase 2 structures","volume":"45","author":"A Briso-Montiano","year":"2022","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"pone.0354138.ref039","doi-asserted-by":"crossref","first-page":"101027","DOI":"10.1016\/j.gim.2023.101027","article-title":"Neurological manifestations in PMM2-congenital disorders of glycosylation (PMM2-CDG): Insights into clinico-radiological characteristics, recommendations for follow-up, and future directions","volume":"26","author":"K Muthusamy","year":"2024","journal-title":"Genet Med"},{"key":"pone.0354138.ref040","doi-asserted-by":"crossref","first-page":"1594118","DOI":"10.3389\/fendo.2025.1594118","article-title":"Phosphomannomutase 2-congenital disorder of glycosylation: exploring the role of N-glycosylation on the endocrine axes","volume":"16","author":"G Del Medico","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0354138.ref041","doi-asserted-by":"crossref","first-page":"102460","DOI":"10.1016\/j.coi.2024.102460","article-title":"Rethinking Toll-like receptor signalling","volume":"91","author":"CE Bryant","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"pone.0354138.ref042","doi-asserted-by":"crossref","first-page":"812774","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity","volume":"13","author":"T Duan","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"pone.0354138.ref043","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.tips.2022.05.004","article-title":"Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions","volume":"43","author":"S Squillace","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"pone.0354138.ref044","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","article-title":"Toll-like receptors and their crosstalk with other innate receptors in infection and immunity","volume":"34","author":"T Kawai","year":"2011","journal-title":"Immunity"},{"issue":"1","key":"pone.0354138.ref045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12979-023-00383-3","article-title":"Toll-like receptor 4 (TLR4): new insight immune and aging","volume":"20","author":"H-J Kim","year":"2023","journal-title":"Immun Ageing"},{"key":"pone.0354138.ref046","doi-asserted-by":"crossref","first-page":"116829","DOI":"10.1016\/j.envpol.2021.116829","article-title":"Bisphenol A: A potential Toll-like receptor 4\/myeloid differentiation factor 2 complex agonist","volume":"278","author":"WAHM Karunarathne","year":"2021","journal-title":"Environ Pollut"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:42:54Z","timestamp":1785260574000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0354138"}},"subtitle":[],"editor":[{"given":"Suresh","family":"Yenugu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0354138","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}